-
Innovation Ranking
NewInnovation Ranking – Larimar Therapeutics Inc
Larimar Therapeutics Inc (Larimar Therapeutics), formerly Zafgen Inc, is a biotechnology company that discovers and develops treatments for rare diseases. It is investigating its lead product candidate CTI-1601 to treat Friedreich’s ataxia, a rare and progressive genetic disease that affects the functioning of multiple organs and systems. The company utilizes its proprietary protein replacement therapy platform to deliver missing proteins into the machinery of cells and treat rare diseases. It works in partnership with Friedreich’s Ataxia Research Alliance, Wake Forest...
-
Product Insights
Friedreich Ataxia – Drugs In Development, 2023
Global Markets Direct’s, ‘Friedreich Ataxia - Drugs In Development, 2023’, provides an overview of the Friedreich Ataxia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Company Profile
Larimar Therapeutics Inc – Company Profile
Larimar Therapeutics Inc (Larimar Therapeutics), formerly Zafgen Inc, is a biotechnology company that discovers and develops treatments for rare diseases. The company is investigating its lead product candidate CTI-1601 to treat Friedreich’s ataxia, a rare and progressive genetic disease that affects the functioning of multiple organs and systems. The company utilizes its proprietary protein replacement therapy platform to deliver missing proteins into the machinery of cells and treat rare diseases. It works in partnership with Friedreich’s Ataxia Research Alliance, Wake...
Add to Basket -
Product Insights
Prader-Willi Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Prader-Willi Syndrome (PWS) Clinical Trials Market Report Overview The Prader-Willi Syndrome (PWS) clinical trial market research report provides an overview of the PWS clinical trials scenario. The report provides top-line data relating to the clinical trials on PWS. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
Friedreich Ataxia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Friedreich Ataxia Clinical Trials Market Report Overview There were a total of 106 Friedreich ataxia clinical trials conducted as of January 2023. The Friedreich ataxia clinical trial market research report provides a comprehensive overview of the market across regions and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. The report includes information about the sponsor types and the prominent sponsors associated with the trials as well. Friedreich Ataxia Clinical Trials...
-
Product Insights
Prader-Willi Syndrome (PWS) Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Prader-Willi Syndrome (PWS) Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Prader-Willi Syndrome (PWS) Clinical trials scenario. This report provides top line data relating to the clinical trials on Prader-Willi Syndrome (PWS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor...